LONDON, ONTARIO--(Marketwire - Sept. 4, 2012) - Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE:SVA) today announced that Dr. Philip Toleikis, President and CEO, will present at the Rodman & Renshaw Annual Global Investment Conference (14th Annual Healthcare Conference) at 4:05 p.m. EDT, September 11th, in the Starlight Center Salon at The Waldorf Astoria Hotel in New York City.
"The invitation to Sernova to present at the New York Rodman and Renshaw Conference provides the Company with an excellent opportunity to gain further exposure to investors and analysts," said Philip Toleikis, President and CEO of Sernova Corp.
Dr. Toleikis will provide an overview of the Company's business strategy and the ongoing Phase I/II clinical trial of the Cell Pouch™ with insulin-producing islets in patients with Type-1 diabetes.
About The Cell Pouch™
The Cell Pouch™ is a proprietary medical device that, following subcutaneous implantation, incorporates with tissue and microvessels forming a natural environment for transplantation of therapeutic cells. Multiple preclinical studies demonstrated the Cell Pouch™ to provide a safe environment for transplantation, as well as long-term efficacy of therapeutic cells. Sernova is currently conducting a Phase I/II human clinical study of the Cell Pouch™ with insulin-producing islets in patients with Type-1 diabetes at the University of Alberta with Dr. James Shapiro as principal investigator. Sernova's goals for the Cell Pouch™ for diabetes include providing a safe and natural site for islets to significantly increase the number of patients currently treated with intraportal delivery of donor islets and to provide a safe environment for virtually unlimited available sources of insulin-secreting cells such as insulin-producing stem cells and xenogeneic cells. This vision combined with local anti-rejection protection of the cells could enable millions of patients with insulin-dependent diabetes to be treated without limitation to availability of cells.
Sernova Corp. is a clinical stage health-sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin-dependent diabetes, using the novel Cell Pouch System™ for transplantation and long-term survival of therapeutic cells and its patented Sertolin™ cell technology which can provide an immune-protected local environment for therapeutic cells.
Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.